Cosette Pharmaceuticals, Inc. Launches Betaine Anhydrous Powder, AB-rated to Cystadane (Betaine Anhydrous for Oral Solution)
March 02, 2023 at 07:00 am EST
Share
Cosette Pharmaceuticals, Inc. has obtained the US marketing rights to Betaine Anhydrous for Oral Solution 180gm ("Betaine") in an agreement with ANI Pharmaceuticals, Inc. and commenced shipping (NDC #0713-0352-81) to customers this week. Betaine is used by patients with homocystinuria, a rare genetic condition where too much homocysteine builds up in the body. This launch will provide patients with homocystinururia, and the healthcare providers delivering care to those patients, with a safe, efficacious and accessible treatment option.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
ANI PHARMACEUTICALS, INC. 
